中国生物制药(01177):贝莫苏拜单抗联合治疗肺癌III期研究数据在2025年ASCO年会公布

金吾财讯
23 May

金吾财讯 | 中国生物制药(01177)公告,集团已在2025年美国临床肿瘤学会(ASCO)年会公布了贝莫苏拜单抗注射液联合化疗后序贯联合盐酸安罗替尼胶囊对比替雷利珠单抗注射液联合化疗用于晚期鳞状非小细胞肺癌(sq-NSCLC)一线治疗的III期临床最新研究成果:试验组中位无进展生存期(mPFS)为10.12个月,与对照组相比疾病进展风险降低36%。“贝莫苏拜单抗联合化疗后序贯联合安罗替尼”方案为全球首个头对头PD-1单抗联合化疗一线治疗sqNSCLC获得显着阳性结果的Ⅲ期临床研究。该方案的上市申请已于今年4月获得中国国家药品监督管理局药品审评中心(CDE)受理。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10